Publications and Reports
Delaware Certificate of Incorporation (620KB)
Medgenics By-Laws (3.3MB)
Medgenics AIM Admission Document (1.2MB)


Company Financial Calendar

Event Date
Half year end 30th June
Interim results announced September
Financial year end 31st December
AGM TBD



Company Financial Reports
Annual Report 2007
Medgenics Admission Document December 2007

Regulatory Disclosures, Announcements and Notifications
July 31, 2008: Medgenics Granted Approval to Commence Its Phase I/II Clinical Study of EPODURE to treat Anemia
July 4, 2008: Response from ISRAEL’S Ministry of Health on its Phase I/II clincal Trial with EPODURE in Anemia

June 30, 2008: Notification of transactions of directors, persons discharging managerial responsibility or connected persons
June 30, 2008: Issue of Equity Total Voting Rights
June 19, 2008: Medgenics announces preliminary results for the year ended 31 December 2007
June 4, 2008: Block Listing Interim Review
May 7, 2008: Medgenics appoints vice president of Clinical Affairs
Apr 30, 2008: Total Voting Rights
Apr 22, 2008: Announcement re Issue of Equity
Apr 14, 2008: Research Update: Medgenics on target to start Phase I/II clinical trials with EPODURE protein therapy for anaemia mid-2008 as planned
Mar 18, 2008: Medgenics consolidates corporate and R&D operations into new office facility
Feb 1, 2008: Lord Steinberg Appointment
Dec 4, 2007: Medgenics Admission to Trading
Dec 4, 2007: Medgenics Block Admission and ISIN update
Preliminary Announcement of AIM Submission